Share Price and Basic Stock Data
Last Updated: February 6, 2026, 9:28 pm
| PEG Ratio | 14.62 |
|---|
Analyst Insight & Comprehensive Analysis
AI Stock Ranker – Real-Time Fundamental Strength Score
Business Overview and Revenue Trends
SMS Pharmaceuticals Ltd operates within the pharmaceuticals sector, focusing on the development and manufacturing of active pharmaceutical ingredients (APIs) and formulations. The company reported a market capitalization of ₹2,951 Cr, with its share price at ₹315. Over the years, SMS Pharmaceuticals has shown varied revenue performance. For instance, sales rose from ₹518 Cr in March 2014 to ₹783 Cr in March 2025, demonstrating a strong growth trajectory. In the trailing twelve months (TTM), sales stood at ₹860 Cr, indicating an upward trend. Quarterly sales figures reflected fluctuations, with the most recent quarter (September 2023) recording ₹167 Cr, a rise from ₹135 Cr in June 2023. This consistent growth aligns with the broader pharmaceutical industry’s resilience, driven by increased demand for healthcare products, especially post-pandemic. However, the company experienced some volatility in quarterly revenues, which could be attributed to market conditions or operational challenges, necessitating strategic adjustments to stabilize sales growth.
Profitability and Efficiency Metrics
SMS Pharmaceuticals reported a net profit of ₹81 Cr, reflecting an improved profitability landscape compared to previous years. The company’s operating profit margin (OPM) stood at a healthy 20%, indicating effective cost management and operational efficiency. Over the last few quarters, OPM has shown variability, peaking at 20% in June 2023 before settling at 17% in September 2023. The return on equity (ROE) was recorded at 11%, while the return on capital employed (ROCE) was slightly higher at 12.2%, both of which are indicative of solid asset utilization. The interest coverage ratio (ICR) of 7.83x suggests that SMS Pharmaceuticals can comfortably meet its interest obligations, showcasing financial stability. However, the cash conversion cycle (CCC) of 238 days raises concerns about working capital efficiency. This extended cycle may signal potential issues in inventory management or receivables collection, requiring close monitoring to ensure liquidity remains healthy.
Balance Sheet Strength and Financial Ratios
As of March 2025, SMS Pharmaceuticals reported total assets of ₹1,186 Cr, with total liabilities at ₹1,186 Cr, indicating a balanced financial structure. The company’s reserves reached ₹751 Cr, providing a solid buffer for future investments and operations. Borrowings stood at ₹324 Cr, reflecting a manageable debt position, as evidenced by a low long-term debt to equity ratio of 0.21x. The price-to-book value (P/BV) ratio was reported at 2.95x, suggesting the stock may be trading at a premium compared to its book value, which is typical for growth-oriented companies in the sector. Furthermore, the current ratio of 1.72x indicates adequate short-term liquidity. However, the quick ratio of 0.84x suggests potential challenges in meeting immediate liabilities without relying on inventory sales. Overall, while the balance sheet exhibits strength, the liquidity ratios warrant attention to ensure operational flexibility.
Shareholding Pattern and Investor Confidence
SMS Pharmaceuticals has a diverse shareholding structure, with promoters holding 68.07% of the company. This majority stake reflects strong control and confidence from the founding members. Foreign Institutional Investors (FIIs) held a minimal stake of 0.28%, while Domestic Institutional Investors (DIIs) accounted for 2.88%. The public’s shareholding stood at 28.77%, indicating a reasonable level of retail investor participation. The number of shareholders increased to 34,157, suggesting growing interest in the company among the investing community. However, the declining percentage of public shareholding from 35.23% in December 2022 to 28.77% in September 2025 may raise concerns about liquidity and market perception. The gradual increase in promoter shareholding also points towards a potential consolidation strategy, which could either enhance stability or signal reduced public engagement. Investor confidence appears cautiously optimistic, but the low institutional presence may limit broader market support.
Outlook, Risks, and Final Insight
Looking ahead, SMS Pharmaceuticals is well-positioned to leverage the growing demand for pharmaceutical products, particularly as it continues to innovate and expand its product offerings. However, the company faces several risks, including fluctuations in raw material prices and regulatory challenges, which could impact margins and operational efficiency. Additionally, the extended cash conversion cycle indicates potential liquidity risks that need addressing to maintain smooth operations. On the upside, if SMS Pharmaceuticals can optimize its inventory management and improve its receivables collection, it could enhance cash flow and profitability. Furthermore, a favorable regulatory environment and increased healthcare spending in India could bolster growth prospects. Therefore, while the company has strong fundamentals, careful management of operational challenges and strategic initiatives will be crucial for unlocking its full potential in the competitive pharmaceutical landscape.
Source: Getaka Fundamental Analysis | Generated using proprietary financial data.
Competitors
| Stock Name ⇩ | Market Cap ⇩ | Current Price ⇩ | High / Low ⇩ | Stock P/E ⇩ | Book Value ⇩ | Dividend Yield ⇩ | ROCE ⇩ | ROE ⇩ | Face Value ⇩ |
|---|---|---|---|---|---|---|---|---|---|
| Lactose (India) Ltd | 122 Cr. | 97.0 | 193/84.3 | 27.0 | 49.6 | 0.00 % | 12.9 % | 9.69 % | 10.0 |
| MPS Pharmaa Ltd | 3.21 Cr. | 1.68 | 4.29/1.68 | 0.33 | 0.00 % | 9.79 % | 59.0 % | 10.0 | |
| Gujarat Themis Biosyn Ltd | 3,540 Cr. | 325 | 479/192 | 74.1 | 24.3 | 0.20 % | 27.3 % | 21.7 % | 1.00 |
| Gujarat Terce Laboratories Ltd | 32.8 Cr. | 44.2 | 82.0/37.2 | 10.6 | 0.00 % | 41.4 % | 14.6 % | 10.0 | |
| Gujarat Inject (Kerala) Ltd | 79.0 Cr. | 53.9 | 54.0/17.0 | 188 | 6.93 | 0.00 % | 13.5 % | 11.0 % | 10.0 |
| Industry Average | 19,602.42 Cr | 1,092.88 | 42.94 | 202.24 | 0.37% | 16.29% | 15.20% | 6.10 |
Quarterly Result
| Metric | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 159 | 149 | 149 | 135 | 167 | 161 | 246 | 164 | 197 | 173 | 248 | 196 | 242 |
| Expenses | 146 | 131 | 126 | 109 | 139 | 133 | 212 | 131 | 165 | 140 | 207 | 157 | 194 |
| Operating Profit | 14 | 18 | 23 | 27 | 28 | 29 | 33 | 33 | 32 | 33 | 41 | 39 | 48 |
| OPM % | 9% | 12% | 16% | 20% | 17% | 18% | 14% | 20% | 16% | 19% | 17% | 20% | 20% |
| Other Income | 1 | 2 | 1 | 1 | 1 | 1 | 2 | 1 | 1 | 2 | 1 | 1 | 1 |
| Interest | 5 | 6 | 6 | 6 | 6 | 6 | 6 | 5 | 5 | 4 | 5 | 6 | 6 |
| Depreciation | 8 | 8 | 8 | 8 | 8 | 8 | 8 | 8 | 9 | 9 | 9 | 10 | 10 |
| Profit before tax | 1 | 6 | 11 | 13 | 15 | 16 | 22 | 22 | 20 | 23 | 29 | 24 | 34 |
| Tax % | 12% | 22% | 24% | 29% | 21% | 26% | 26% | 25% | 28% | 24% | 29% | 24% | 26% |
| Net Profit | 1 | 5 | 8 | 9 | 12 | 12 | 16 | 16 | 14 | 17 | 21 | 18 | 25 |
| EPS in Rs | 0.09 | 0.59 | 0.95 | 1.10 | 1.42 | 1.44 | 1.88 | 1.93 | 1.68 | 2.03 | 2.33 | 2.05 | 2.68 |
Last Updated: December 29, 2025, 2:32 am
Below is a detailed analysis of the quarterly data for SMS Pharmaceuticals Ltd based on the most recent figures (Sep 2025) and their trends compared to the previous period:
- For Sales, as of Sep 2025, the value is 242.00 Cr.. The value appears strong and on an upward trend. It has increased from 196.00 Cr. (Jun 2025) to 242.00 Cr., marking an increase of 46.00 Cr..
- For Expenses, as of Sep 2025, the value is 194.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 157.00 Cr. (Jun 2025) to 194.00 Cr., marking an increase of 37.00 Cr..
- For Operating Profit, as of Sep 2025, the value is 48.00 Cr.. The value appears strong and on an upward trend. It has increased from 39.00 Cr. (Jun 2025) to 48.00 Cr., marking an increase of 9.00 Cr..
- For OPM %, as of Sep 2025, the value is 20.00%. The value remains steady. There is no change compared to the previous period (Jun 2025) which recorded 20.00%.
- For Other Income, as of Sep 2025, the value is 1.00 Cr.. The value remains steady. There is no change compared to the previous period (Jun 2025) which recorded 1.00 Cr..
- For Interest, as of Sep 2025, the value is 6.00 Cr.. The value remains steady. There is no change compared to the previous period (Jun 2025) which recorded 6.00 Cr..
- For Depreciation, as of Sep 2025, the value is 10.00 Cr.. The value remains steady. There is no change compared to the previous period (Jun 2025) which recorded 10.00 Cr..
- For Profit before tax, as of Sep 2025, the value is 34.00 Cr.. The value appears strong and on an upward trend. It has increased from 24.00 Cr. (Jun 2025) to 34.00 Cr., marking an increase of 10.00 Cr..
- For Tax %, as of Sep 2025, the value is 26.00%. The value appears to be increasing, which may not be favorable. It has increased from 24.00% (Jun 2025) to 26.00%, marking an increase of 2.00%.
- For Net Profit, as of Sep 2025, the value is 25.00 Cr.. The value appears strong and on an upward trend. It has increased from 18.00 Cr. (Jun 2025) to 25.00 Cr., marking an increase of 7.00 Cr..
- For EPS in Rs, as of Sep 2025, the value is 2.68. The value appears strong and on an upward trend. It has increased from 2.05 (Jun 2025) to 2.68, marking an increase of 0.63.
Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.
Profit & Loss - Annual Report
Last Updated: December 15, 2025, 4:37 am
| Metric | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 518 | 587 | 611 | 438 | 463 | 465 | 412 | 563 | 520 | 522 | 709 | 783 | 860 |
| Expenses | 461 | 500 | 522 | 363 | 369 | 375 | 332 | 442 | 405 | 467 | 592 | 643 | 698 |
| Operating Profit | 57 | 86 | 89 | 75 | 93 | 90 | 80 | 121 | 115 | 55 | 117 | 140 | 162 |
| OPM % | 11% | 15% | 15% | 17% | 20% | 19% | 19% | 22% | 22% | 10% | 16% | 18% | 19% |
| Other Income | 2 | 16 | 4 | 1 | 2 | 3 | 5 | 3 | 5 | 5 | 4 | 6 | 6 |
| Interest | 14 | 18 | 17 | 16 | 15 | 12 | 12 | 11 | 19 | 22 | 24 | 19 | 21 |
| Depreciation | 13 | 17 | 19 | 19 | 20 | 19 | 22 | 22 | 32 | 32 | 32 | 34 | 37 |
| Profit before tax | 32 | 67 | 56 | 42 | 60 | 62 | 51 | 91 | 69 | 6 | 66 | 93 | 110 |
| Tax % | 36% | 48% | 26% | 14% | 33% | 34% | 36% | 33% | 1% | 26% | 25% | 27% | |
| Net Profit | 20 | 35 | 42 | 36 | 40 | 41 | 33 | 61 | 68 | 4 | 49 | 68 | 81 |
| EPS in Rs | 2.40 | 4.15 | 4.92 | 4.20 | 4.78 | 4.89 | 3.86 | 7.20 | 8.03 | 0.48 | 5.83 | 7.71 | 9.09 |
| Dividend Payout % | 8% | 5% | 4% | 5% | 5% | 5% | 6% | 4% | 4% | 62% | 7% | 5% |
YoY Net Profit Growth
| Year | 2014-2015 | 2015-2016 | 2016-2017 | 2017-2018 | 2018-2019 | 2019-2020 | 2020-2021 | 2021-2022 | 2022-2023 | 2023-2024 | 2024-2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| YoY Net Profit Growth (%) | 75.00% | 20.00% | -14.29% | 11.11% | 2.50% | -19.51% | 84.85% | 11.48% | -94.12% | 1125.00% | 38.78% |
| Change in YoY Net Profit Growth (%) | 0.00% | -55.00% | -34.29% | 25.40% | -8.61% | -22.01% | 104.36% | -73.37% | -105.59% | 1219.12% | -1086.22% |
SMS Pharmaceuticals Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 11 years from 2014-2015 to 2024-2025.
Growth
| Compounded Sales Growth | |
|---|---|
| 10 Years: | 3% |
| 5 Years: | 14% |
| 3 Years: | 15% |
| TTM: | 10% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | 7% |
| 5 Years: | 16% |
| 3 Years: | 0% |
| TTM: | 24% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | 17% |
| 5 Years: | 22% |
| 3 Years: | 39% |
| 1 Year: | -31% |
| Return on Equity | |
|---|---|
| 10 Years: | 11% |
| 5 Years: | 10% |
| 3 Years: | 7% |
| Last Year: | 11% |
Last Updated: September 5, 2025, 1:31 pm
Balance Sheet
Last Updated: December 4, 2025, 2:00 am
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Sep 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 8 | 8 | 8 | 8 | 8 | 8 | 8 | 8 | 8 | 8 | 8 | 9 | 9 |
| Reserves | 213 | 246 | 286 | 254 | 293 | 331 | 359 | 420 | 485 | 487 | 562 | 664 | 751 |
| Borrowings | 167 | 167 | 204 | 149 | 146 | 144 | 157 | 255 | 263 | 254 | 281 | 311 | 324 |
| Other Liabilities | 120 | 119 | 158 | 89 | 72 | 93 | 103 | 147 | 126 | 165 | 217 | 202 | 221 |
| Total Liabilities | 509 | 540 | 656 | 501 | 519 | 577 | 627 | 830 | 883 | 914 | 1,068 | 1,186 | 1,305 |
| Fixed Assets | 247 | 277 | 370 | 290 | 279 | 281 | 280 | 457 | 438 | 412 | 437 | 533 | 517 |
| CWIP | 39 | 29 | 13 | 8 | 8 | 18 | 42 | 7 | 11 | 33 | 30 | 35 | 50 |
| Investments | 6 | 13 | 21 | 37 | 45 | 45 | 45 | 45 | 45 | 45 | 45 | 45 | 48 |
| Other Assets | 217 | 221 | 252 | 166 | 187 | 232 | 259 | 321 | 389 | 424 | 556 | 573 | 690 |
| Total Assets | 509 | 540 | 656 | 501 | 519 | 577 | 627 | 830 | 883 | 914 | 1,068 | 1,186 | 1,305 |
Below is a detailed analysis of the balance sheet data for SMS Pharmaceuticals Ltd based on the most recent figures (Sep 2025) and their trends compared to the previous period:
- For Equity Capital, as of Sep 2025, the value is 9.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 9.00 Cr..
- For Reserves, as of Sep 2025, the value is 751.00 Cr.. The value appears strong and on an upward trend. It has increased from 664.00 Cr. (Mar 2025) to 751.00 Cr., marking an increase of 87.00 Cr..
- For Borrowings, as of Sep 2025, the value is 324.00 Cr.. The value appears to be increasing, which may not be favorable. Additionally, since Reserves exceed Borrowings, this is considered a positive sign. It has increased from 311.00 Cr. (Mar 2025) to 324.00 Cr., marking an increase of 13.00 Cr..
- For Other Liabilities, as of Sep 2025, the value is 221.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 202.00 Cr. (Mar 2025) to 221.00 Cr., marking an increase of 19.00 Cr..
- For Total Liabilities, as of Sep 2025, the value is 1,305.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 1,186.00 Cr. (Mar 2025) to 1,305.00 Cr., marking an increase of 119.00 Cr..
- For Fixed Assets, as of Sep 2025, the value is 517.00 Cr.. The value appears to be declining and may need further review. It has decreased from 533.00 Cr. (Mar 2025) to 517.00 Cr., marking a decrease of 16.00 Cr..
- For CWIP, as of Sep 2025, the value is 50.00 Cr.. The value appears strong and on an upward trend. It has increased from 35.00 Cr. (Mar 2025) to 50.00 Cr., marking an increase of 15.00 Cr..
- For Investments, as of Sep 2025, the value is 48.00 Cr.. The value appears strong and on an upward trend. It has increased from 45.00 Cr. (Mar 2025) to 48.00 Cr., marking an increase of 3.00 Cr..
- For Other Assets, as of Sep 2025, the value is 690.00 Cr.. The value appears strong and on an upward trend. It has increased from 573.00 Cr. (Mar 2025) to 690.00 Cr., marking an increase of 117.00 Cr..
- For Total Assets, as of Sep 2025, the value is 1,305.00 Cr.. The value appears strong and on an upward trend. It has increased from 1,186.00 Cr. (Mar 2025) to 1,305.00 Cr., marking an increase of 119.00 Cr..
Notably, the Reserves (751.00 Cr.) exceed the Borrowings (324.00 Cr.), indicating a solid financial buffer.
Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.
Cash Flow
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
Free Cash Flow
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Free Cash Flow | -110.00 | -81.00 | -115.00 | -74.00 | -53.00 | -54.00 | -77.00 | -134.00 | -148.00 | -199.00 | -164.00 | -171.00 |
Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)
Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.
Financial Efficiency Indicators
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 39 | 37 | 36 | 18 | 19 | 20 | 43 | 68 | 34 | 104 | 122 | 95 |
| Inventory Days | 90 | 81 | 106 | 114 | 135 | 170 | 191 | 148 | 333 | 243 | 201 | 238 |
| Days Payable | 59 | 58 | 79 | 82 | 49 | 59 | 66 | 70 | 97 | 117 | 130 | 95 |
| Cash Conversion Cycle | 70 | 61 | 63 | 50 | 105 | 131 | 169 | 146 | 270 | 230 | 192 | 238 |
| Working Capital Days | 9 | 19 | 19 | -2 | 27 | 39 | 57 | 48 | 94 | 104 | 85 | 88 |
| ROCE % | 12% | 21% | 16% | 13% | 18% | 16% | 13% | 17% | 12% | 4% | 11% | 12% |
Mutual Fund Holdings
| Fund Name | No of Shares | AUM (%) | Amount Invested (Cr) | Previous Number of Shares | Previous Date | Percentage Change |
|---|---|---|---|---|---|---|
| Quant Small Cap Fund | 1,859,681 | 0.19 | 57.72 | N/A | N/A | N/A |
| Quant Healthcare Fund | 1,118,647 | 9.58 | 34.72 | N/A | N/A | N/A |
Key Financial Ratios
| Month | Mar 25 | Mar 24 | Mar 23 | Mar 22 | Mar 21 |
|---|---|---|---|---|---|
| FaceValue | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 |
| Basic EPS (Rs.) | 8.16 | 5.89 | -0.83 | 7.35 | 7.39 |
| Diluted EPS (Rs.) | 8.16 | 5.89 | -0.83 | 7.35 | 7.39 |
| Cash EPS (Rs.) | 11.48 | 9.54 | 4.25 | 11.82 | 9.83 |
| Book Value[Excl.RevalReserv]/Share (Rs.) | 72.15 | 63.36 | 54.40 | 55.56 | 48.50 |
| Book Value[Incl.RevalReserv]/Share (Rs.) | 72.15 | 63.36 | 54.40 | 55.56 | 48.50 |
| Revenue From Operations / Share (Rs.) | 88.29 | 83.79 | 61.67 | 61.41 | 66.53 |
| PBDIT / Share (Rs.) | 16.38 | 14.30 | 7.02 | 14.12 | 14.71 |
| PBIT / Share (Rs.) | 12.51 | 10.58 | 3.22 | 10.32 | 12.08 |
| PBT / Share (Rs.) | 10.42 | 7.81 | 0.63 | 8.09 | 10.76 |
| Net Profit / Share (Rs.) | 7.60 | 5.81 | 0.45 | 8.02 | 7.20 |
| NP After MI And SOA / Share (Rs.) | 7.80 | 5.89 | -0.83 | 7.35 | 7.39 |
| PBDIT Margin (%) | 18.55 | 17.07 | 11.37 | 22.99 | 22.11 |
| PBIT Margin (%) | 14.16 | 12.62 | 5.22 | 16.80 | 18.16 |
| PBT Margin (%) | 11.79 | 9.32 | 1.02 | 13.17 | 16.17 |
| Net Profit Margin (%) | 8.61 | 6.93 | 0.74 | 13.05 | 10.82 |
| NP After MI And SOA Margin (%) | 8.83 | 7.02 | -1.35 | 11.96 | 11.10 |
| Return on Networth / Equity (%) | 10.80 | 9.29 | -1.53 | 13.23 | 15.23 |
| Return on Capital Employeed (%) | 13.38 | 12.75 | 4.36 | 13.17 | 16.54 |
| Return On Assets (%) | 5.99 | 4.81 | -0.80 | 7.23 | 7.69 |
| Long Term Debt / Equity (X) | 0.21 | 0.22 | 0.26 | 0.31 | 0.36 |
| Total Debt / Equity (X) | 0.48 | 0.52 | 0.54 | 0.55 | 0.53 |
| Asset Turnover Ratio (%) | 0.71 | 0.74 | 0.60 | 0.61 | 0.78 |
| Current Ratio (X) | 1.72 | 1.62 | 1.61 | 1.92 | 1.59 |
| Quick Ratio (X) | 0.84 | 0.91 | 0.73 | 0.64 | 0.88 |
| Inventory Turnover Ratio (X) | 3.02 | 1.86 | 1.26 | 1.99 | 2.35 |
| Dividend Payout Ratio (NP) (%) | 4.89 | 5.09 | -35.97 | 4.08 | 0.00 |
| Dividend Payout Ratio (CP) (%) | 3.27 | 3.12 | 10.13 | 2.69 | 0.00 |
| Earning Retention Ratio (%) | 95.11 | 94.91 | 135.97 | 95.92 | 0.00 |
| Cash Earning Retention Ratio (%) | 96.73 | 96.88 | 89.87 | 97.31 | 0.00 |
| Interest Coverage Ratio (X) | 7.83 | 5.16 | 2.71 | 6.33 | 11.16 |
| Interest Coverage Ratio (Post Tax) (X) | 4.64 | 3.10 | 1.18 | 4.60 | 6.46 |
| Enterprise Value (Cr.) | 2151.85 | 1748.52 | 734.33 | 1007.49 | 1231.25 |
| EV / Net Operating Revenue (X) | 2.75 | 2.47 | 1.41 | 1.94 | 2.19 |
| EV / EBITDA (X) | 14.82 | 14.44 | 12.36 | 8.43 | 9.88 |
| MarketCap / Net Operating Revenue (X) | 2.41 | 2.13 | 0.93 | 1.53 | 1.87 |
| Retention Ratios (%) | 95.10 | 94.90 | 135.97 | 95.91 | 0.00 |
| Price / BV (X) | 2.95 | 2.81 | 1.06 | 1.69 | 2.57 |
| Price / Net Operating Revenue (X) | 2.41 | 2.13 | 0.93 | 1.53 | 1.87 |
| EarningsYield | 0.03 | 0.03 | -0.01 | 0.07 | 0.05 |
After reviewing the key financial ratios for SMS Pharmaceuticals Ltd, here is a detailed analysis based on the latest available data and recent trends:
- For FaceValue, as of Mar 25, the value is 1.00. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 1.00.
- For Basic EPS (Rs.), as of Mar 25, the value is 8.16. This value is within the healthy range. It has increased from 5.89 (Mar 24) to 8.16, marking an increase of 2.27.
- For Diluted EPS (Rs.), as of Mar 25, the value is 8.16. This value is within the healthy range. It has increased from 5.89 (Mar 24) to 8.16, marking an increase of 2.27.
- For Cash EPS (Rs.), as of Mar 25, the value is 11.48. This value is within the healthy range. It has increased from 9.54 (Mar 24) to 11.48, marking an increase of 1.94.
- For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 72.15. It has increased from 63.36 (Mar 24) to 72.15, marking an increase of 8.79.
- For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 72.15. It has increased from 63.36 (Mar 24) to 72.15, marking an increase of 8.79.
- For Revenue From Operations / Share (Rs.), as of Mar 25, the value is 88.29. It has increased from 83.79 (Mar 24) to 88.29, marking an increase of 4.50.
- For PBDIT / Share (Rs.), as of Mar 25, the value is 16.38. This value is within the healthy range. It has increased from 14.30 (Mar 24) to 16.38, marking an increase of 2.08.
- For PBIT / Share (Rs.), as of Mar 25, the value is 12.51. This value is within the healthy range. It has increased from 10.58 (Mar 24) to 12.51, marking an increase of 1.93.
- For PBT / Share (Rs.), as of Mar 25, the value is 10.42. This value is within the healthy range. It has increased from 7.81 (Mar 24) to 10.42, marking an increase of 2.61.
- For Net Profit / Share (Rs.), as of Mar 25, the value is 7.60. This value is within the healthy range. It has increased from 5.81 (Mar 24) to 7.60, marking an increase of 1.79.
- For NP After MI And SOA / Share (Rs.), as of Mar 25, the value is 7.80. This value is within the healthy range. It has increased from 5.89 (Mar 24) to 7.80, marking an increase of 1.91.
- For PBDIT Margin (%), as of Mar 25, the value is 18.55. This value is within the healthy range. It has increased from 17.07 (Mar 24) to 18.55, marking an increase of 1.48.
- For PBIT Margin (%), as of Mar 25, the value is 14.16. This value is within the healthy range. It has increased from 12.62 (Mar 24) to 14.16, marking an increase of 1.54.
- For PBT Margin (%), as of Mar 25, the value is 11.79. This value is within the healthy range. It has increased from 9.32 (Mar 24) to 11.79, marking an increase of 2.47.
- For Net Profit Margin (%), as of Mar 25, the value is 8.61. This value is within the healthy range. It has increased from 6.93 (Mar 24) to 8.61, marking an increase of 1.68.
- For NP After MI And SOA Margin (%), as of Mar 25, the value is 8.83. This value is within the healthy range. It has increased from 7.02 (Mar 24) to 8.83, marking an increase of 1.81.
- For Return on Networth / Equity (%), as of Mar 25, the value is 10.80. This value is below the healthy minimum of 15. It has increased from 9.29 (Mar 24) to 10.80, marking an increase of 1.51.
- For Return on Capital Employeed (%), as of Mar 25, the value is 13.38. This value is within the healthy range. It has increased from 12.75 (Mar 24) to 13.38, marking an increase of 0.63.
- For Return On Assets (%), as of Mar 25, the value is 5.99. This value is within the healthy range. It has increased from 4.81 (Mar 24) to 5.99, marking an increase of 1.18.
- For Long Term Debt / Equity (X), as of Mar 25, the value is 0.21. This value is within the healthy range. It has decreased from 0.22 (Mar 24) to 0.21, marking a decrease of 0.01.
- For Total Debt / Equity (X), as of Mar 25, the value is 0.48. This value is within the healthy range. It has decreased from 0.52 (Mar 24) to 0.48, marking a decrease of 0.04.
- For Asset Turnover Ratio (%), as of Mar 25, the value is 0.71. It has decreased from 0.74 (Mar 24) to 0.71, marking a decrease of 0.03.
- For Current Ratio (X), as of Mar 25, the value is 1.72. This value is within the healthy range. It has increased from 1.62 (Mar 24) to 1.72, marking an increase of 0.10.
- For Quick Ratio (X), as of Mar 25, the value is 0.84. This value is below the healthy minimum of 1. It has decreased from 0.91 (Mar 24) to 0.84, marking a decrease of 0.07.
- For Inventory Turnover Ratio (X), as of Mar 25, the value is 3.02. This value is below the healthy minimum of 4. It has increased from 1.86 (Mar 24) to 3.02, marking an increase of 1.16.
- For Dividend Payout Ratio (NP) (%), as of Mar 25, the value is 4.89. This value is below the healthy minimum of 20. It has decreased from 5.09 (Mar 24) to 4.89, marking a decrease of 0.20.
- For Dividend Payout Ratio (CP) (%), as of Mar 25, the value is 3.27. This value is below the healthy minimum of 20. It has increased from 3.12 (Mar 24) to 3.27, marking an increase of 0.15.
- For Earning Retention Ratio (%), as of Mar 25, the value is 95.11. This value exceeds the healthy maximum of 70. It has increased from 94.91 (Mar 24) to 95.11, marking an increase of 0.20.
- For Cash Earning Retention Ratio (%), as of Mar 25, the value is 96.73. This value exceeds the healthy maximum of 70. It has decreased from 96.88 (Mar 24) to 96.73, marking a decrease of 0.15.
- For Interest Coverage Ratio (X), as of Mar 25, the value is 7.83. This value is within the healthy range. It has increased from 5.16 (Mar 24) to 7.83, marking an increase of 2.67.
- For Interest Coverage Ratio (Post Tax) (X), as of Mar 25, the value is 4.64. This value is within the healthy range. It has increased from 3.10 (Mar 24) to 4.64, marking an increase of 1.54.
- For Enterprise Value (Cr.), as of Mar 25, the value is 2,151.85. It has increased from 1,748.52 (Mar 24) to 2,151.85, marking an increase of 403.33.
- For EV / Net Operating Revenue (X), as of Mar 25, the value is 2.75. This value is within the healthy range. It has increased from 2.47 (Mar 24) to 2.75, marking an increase of 0.28.
- For EV / EBITDA (X), as of Mar 25, the value is 14.82. This value is within the healthy range. It has increased from 14.44 (Mar 24) to 14.82, marking an increase of 0.38.
- For MarketCap / Net Operating Revenue (X), as of Mar 25, the value is 2.41. This value is within the healthy range. It has increased from 2.13 (Mar 24) to 2.41, marking an increase of 0.28.
- For Retention Ratios (%), as of Mar 25, the value is 95.10. This value exceeds the healthy maximum of 70. It has increased from 94.90 (Mar 24) to 95.10, marking an increase of 0.20.
- For Price / BV (X), as of Mar 25, the value is 2.95. This value is within the healthy range. It has increased from 2.81 (Mar 24) to 2.95, marking an increase of 0.14.
- For Price / Net Operating Revenue (X), as of Mar 25, the value is 2.41. This value is within the healthy range. It has increased from 2.13 (Mar 24) to 2.41, marking an increase of 0.28.
- For EarningsYield, as of Mar 25, the value is 0.03. This value is below the healthy minimum of 5. There is no change compared to the previous period (Mar 24) which recorded 0.03.
Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.
Strength and Weakness
| Strength | Weakness |
|---|---|
|
|
Stock Analysis
- Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in SMS Pharmaceuticals Ltd:
- Net Profit Margin: 8.61%
- Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
- ROCE: 13.38% (Industry Average ROCE: 16.29%)
- ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
- ROE%: 10.8% (Industry Average ROE: 15.2%)
- ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
- Interest Coverage Ratio (Post Tax): 4.64
- Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
- Quick Ratio: 0.84
- Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
- Stock P/E: 36.7 (Industry average Stock P/E: 42.94)
- Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
- Total Debt / Equity: 0.48
- Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
Stock Rating: - Net Profit Margin: 8.61%
About the Company - Qualitative Analysis
| INDUSTRY | ADDRESS | CONTACT |
|---|---|---|
| Pharmaceuticals | Plot No. 72, H.No. 8-2-334 / 3 & 4, Road No. 5, Opp. SBI Executive Enclave, Hyderabad Telangana 500034 | Contact not found |
| Management | |
|---|---|
| Name | Position Held |
| Mr. Ramesh Babu Potluri | Chairman & Managing Director |
| Mr. Vamsi Krishna Potluri | Executive Director |
| Dr. Sunkara Venkata Satya Shiva Prasad | Non Exe.Non Ind.Director |
| Mr. Trilok Potluri | Non Exe.Non Ind.Director |
| Mr. Sarvepalli Srinivas | Ind. Non-Executive Director |
| Mr. Sharvan Kudaravalli | Ind. Non-Executive Director |
| Dr. Suresh Kumar Gangavarapu | Ind. Non-Executive Director |
| Mrs. Shanti Sree Bolleni | Ind. Non-Executive Director |
FAQ
What is the intrinsic value of SMS Pharmaceuticals Ltd?
SMS Pharmaceuticals Ltd's intrinsic value (as of 06 February 2026) is ₹269.17 which is 15.36% lower the current market price of ₹318.00, indicating overvalued. Calculated using the PE ratio method, this valuation considers the company's ₹2,974 Cr. market cap, FY2025-2026 high/low of ₹360/175, reserves of ₹751 Cr, and liabilities of ₹1,305 Cr.
What is the Market Cap of SMS Pharmaceuticals Ltd?
The Market Cap of SMS Pharmaceuticals Ltd is 2,974 Cr..
What is the current Stock Price of SMS Pharmaceuticals Ltd as on 06 February 2026?
The current stock price of SMS Pharmaceuticals Ltd as on 06 February 2026 is ₹318.
What is the High / Low of SMS Pharmaceuticals Ltd stocks in FY 2025-2026?
In FY 2025-2026, the High / Low of SMS Pharmaceuticals Ltd stocks is ₹360/175.
What is the Stock P/E of SMS Pharmaceuticals Ltd?
The Stock P/E of SMS Pharmaceuticals Ltd is 36.7.
What is the Book Value of SMS Pharmaceuticals Ltd?
The Book Value of SMS Pharmaceuticals Ltd is 81.2.
What is the Dividend Yield of SMS Pharmaceuticals Ltd?
The Dividend Yield of SMS Pharmaceuticals Ltd is 0.13 %.
What is the ROCE of SMS Pharmaceuticals Ltd?
The ROCE of SMS Pharmaceuticals Ltd is 12.2 %.
What is the ROE of SMS Pharmaceuticals Ltd?
The ROE of SMS Pharmaceuticals Ltd is 11.0 %.
What is the Face Value of SMS Pharmaceuticals Ltd?
The Face Value of SMS Pharmaceuticals Ltd is 1.00.